1 – 10 of 2031
- show: 10
- |
- sort: year (new to old)
- |
- Export
- 2023
- Comparison of prone and supine positioning for breast cancer radiotherapy using REQUITE data : dosimetry, acute and two years physician and patient-reported outcomes (2023) ACTA ONCOLOGICA. 62(9). p.1036-1044
- Patient-reported outcomes and functional exercise capacity in a real-life setting in non-small cell lung cancer patients undergoing stereotactic body radiotherapy : the Lung PLUS study (2023) FRONTIERS IN ONCOLOGY. 13.
- Microbiome and metabolome dynamics during radiotherapy for prostate cancer (2023) RADIOTHERAPY AND ONCOLOGY. 189.
- Experiences of men with prostate cancer participating in a clinical pathway with a supervised group-based exercise program to combat androgen deprivation-induced side effects : a qualitative focus group study (2023) SEMINARS IN ONCOLOGY NURSING. 39(3).
- WNT pathway mutations in metachronous oligometastatic castration-sensitive prostate cancer (2023) INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS. 115(5). p.1095-1101
- Checkpoint inhibitors in combination with stereotactic body radiotherapy in patients with advanced solid tumors : the CHEERS phase 2 randomized clinical trial (2023) JAMA ONCOLOGY. 9(9). p.1205-1213
- Accuracy and reliability of a commercial treatment planning system in nontarget regions in modern prostate radiotherapy (2023) JOURNAL OF APPLIED CLINICAL MEDICAL PHYSICS. 24(8).
- Developing time-driven activity-based costing at the national level to support policy recommendations for radiation oncology in Belgium (2023) JOURNAL OF ACCOUNTING AND PUBLIC POLICY. 42(1).
- PEACE V—Salvage Treatment of OligoRecurrent nodal prostate cancer Metastases (STORM) : acute toxicity of a randomized phase 2 trial (2023) EUROPEAN UROLOGY ONCOLOGY.
- Clinical and genomic differences between advanced molecular imaging-detected and conventional imaging-detected metachronous oligometastatic castration-sensitive prostate cancer (2023) EUROPEAN UROLOGY.